Safety and efficacy of intravenous hydralazine and labetalol for the treatment of asymptomatic hypertension in hospitalised patients: A systematic review.

Jocelyn R CawoskiKatie A DeBiasioScott W DonnachieElizabeth A TimanusDavid E ZimmermanAnthony J GuarascioCourtney A MonteparaJordan R Covvey Branden D Nemecek

Published in: International journal of clinical practice (2021)

The studies identified in this review raise concerns regarding the safety of IV hydralazine and labetalol in non-emergent HTN. Despite relatively broad clinical experience with these drugs, experimental investigations regarding their utility are recommended.

Keyphrases

end stage renal disease
blood pressure
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
high dose
low dose